Intarcia announces two presentations at 50th EASD meeting: confirms pivotal phase 3 data announcement for ITCA 650 in type 2 diabetes in 4q
Posted: 12 September 2014 | | No comments yet
Intarcia Therapeutics, Inc. announced its participation in the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place in Vienna September 15-19…
Intarcia Therapeutics, Inc.today announced its participation in the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place in Vienna September 15-19. Intarcia’s lead product candidate, ITCA 650, (exenatide, delivered continuously through a matchstick-size, subcutaneous osmotic pump) is currently in multiple global Phase 3 trials and could become the first once-yearly, injection-free GLP-1 therapy for the treatment of type 2 diabetes. Intarcia’s global ITCA 650 phase 3 program (FREEDOM program in over 4,000 patients) remains on track; Company confirms plans to announce final top-line results from two phase 3 trials in 4Q 2014.
“Efficacy and Tolerability of ITCA 650 (continuous subcutaneous exenatide) in Poorly Controlled Type 2 Diabetes with Baseline A1C >10%.” SEPTEMBER 19th
On Friday, September 19 at 11:45 am CEST, Robert Henry, M.D., Chief, VA Endocrinology & Metabolism and Professor of Medicine in Residence at UCSD, will give a live oral presentation of data from Intarcia’s FREEDOM-HBL (High Baseline) trial. The data are interim 6-month results from an open-label Phase 3 clinical trial of ITCA 650 in patients with type 2 diabetes whose HbA1c baseline levels were quite high between 10-12%.
“The Burden of ‘Serial Non-adherence’ in Type 2 Diabetic Patients.” SEPTEMBER 17th
On Wednesday, September 17th at 2:15 pm CEST, Christian Frois, Ph.D., of Analysis Group, Inc. will present the first data in a series of planned retrospective studies sponsored by Intarcia to characterize the prevalence of poor control of HbA1c in type 2 diabetes, and the contributory role of non-adherence and serial non-adherence, more accurately characterizing the economic burden associated with non-adherence with anti-diabetic therapy – including hypoglycemia-related healthcare costs. The study also identifies key predictors of non-adherence to anti-diabetic therapy, predictors that could enable clinicians to take preemptive action to improve outcomes. The presentation #1054 will be delivered in the Poster Session 088, Lifestyle and Delivery of Care.
